论文部分内容阅读
乳癌的发生发展受内分泌调控 ,已证实至少有 1/ 3的乳癌患者是激素依赖性的 ,减低体内雌激素水平 ,即有利于乳癌的治疗。目前常用的内分泌治疗药物分为抗雌激素类 ,芳香化酶抑制剂 ,L HRH类似物 ,孕激素类等 ,可根据患者的月经状态 ,全身状况 ,激素受体情况 ,远处转移的受侵器官等情况具体选用。内分泌治疗应用于新辅助治疗及乳癌的预防是目前研究的热点 ,已有报道证实其可提高乳癌患者的预后并可在一定程度上降低乳癌发生的风险。
The occurrence and development of breast cancer is regulated by endocrinology. It has been confirmed that at least one third of breast cancer patients are hormone-dependent and reduce the level of estrogen in the body, which is beneficial to the treatment of breast cancer. Currently used endocrine therapy drugs are divided into anti-estrogens, aromatase inhibitors, L HRH analogues, progestogens, etc., can be based on the patient’s menstrual status, general condition, hormone receptor conditions, invasion of distant metastases Specific selection of organs and other conditions. The application of endocrine therapy to neoadjuvant treatment and prevention of breast cancer is currently a hot topic. It has been reported that it can improve the prognosis of breast cancer patients and can reduce the risk of breast cancer to a certain extent.